The value of chemotherapy delivery at specific times of the day to optimize efficacy and minimize adverse effects in hematologic malignancy remains unknown. An interdisciplinary research team discovers its benefit by analyzing cohorts of diffuse large B cell lymphoma (DLBCL)* patients: Chemotherapy in the afternoon significantly improves treatment outcomes of female patients while there is no difference depending on treatment time in male patients.
